Should I Buy BKSY? BKSY 2026 Analysis - Intellectia AI™

Loading...

Should You Buy Blacksky Technology Inc (BKSY) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

22.850

1 Day change

8.86%

52 Week Range

33.200

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now at ~$23.93 pre-market: price is sitting just below key resistance (pivot ~24.80) with weakening/negative momentum signals.
Options positioning is bullish (very low put/call ratios), but implied volatility is extremely high, suggesting this is a sentiment-driven, high-risk momentum setup rather than a clean technical entry.
News flow is positive (new seven-figure Gen-3 defense contracts), but the stock is already pricing a lot of optimism while recent fundamentals show revenue contraction.
No notable hedge fund/insider accumulation signals provided; no politician/congress activity to confirm a “follow-the-smart-money” tailwind.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram (-0.723) remains below zero (bearish), though it is negatively contracting (downside momentum is easing, not reversing).
RSI: RSI(6) ~45.3 (neutral), consistent with consolidation rather than a strong uptrend.
Moving averages: Converging MAs imply a tightening range and lack of directional conviction.
Levels: Price (~23.93) is below Pivot 24.80 (near-term resistance). Support: S1 ~21.89 then S2 ~20.10. Resistance: Pivot 24.80 then R1 ~27.71.
Pattern/forecast signal: Similar-pattern stats lean mildly negative (next day ~50% chance of ~-1.07%; next month bias ~-1.6%), supporting a “not-chasing” stance here.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios are very low (bullish skew toward calls), indicating traders are positioned for upside.
Activity: Today’s option volume vs 30-day average is extremely elevated (43.51), suggesting a speculative/event-driven burst of interest.
Volatility: IV 30d ~106% vs historical vol ~113%; IV percentile 70 (options expensive vs typical), which often accompanies sharp swings and makes timing/entry more punishing if you’re wrong.
Positioning backdrop: Call OI (37,990) materially above Put OI (12,283), reinforcing bullish positioning but also signaling crowding risk near resistance.

Technical Summary

dotted line Image

Sell

5

Buy

6

Positive Catalysts

Multiple seven-figure Gen-3 Assured services contracts with an international defense customer: supports “land-and-expand” and strengthens defense vertical credibility.

Neutral/Negative Catalysts

revenue fell -13% YoY, undermining the near-term growth narrative.
with MACD still negative.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $19.62M, down -13.0% YoY (core negative).
Profitability: Net income improved to -$15.34M (loss narrowed, +21.83% YoY improvement), but still meaningfully negative.
EPS: -0.44, worse YoY (-33.33%), indicating per-share losses widened despite net loss improvement (likely share count/other factors).
Gross margin: 25.18%, up +18.94% YoY (a genuine quality improvement), but not yet enough to offset top-line softness.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings skew positive (mostly Buy), but multiple firms cut price targets after weak results—overall a “Buy, but temper expectations/timing” message.
Jefferies (2025-12-22): Initiated Buy, PT $23; highlights differentiated imagery + refreshed constellation by end-2026; sees ~25% annual topline growth and sales doubling by 2028.
Deutsche Bank (2025-11-07): Buy maintained; PT cut to $20 from $25 (more cautious valuation/timing).
Lake Street (2025-11-07): Buy maintained; PT cut to $26 from $28; encouraged by international momentum and Gen-3 progress despite weak quarter.
Clear Street (2025-11-07): Hold maintained; PT cut to $20 from $24; cites more gradual Gen-3 rollout and budget uncertainty.
Wall Street pros vs cons view: Pros—defense demand + Gen-3 ramp + international expansion potential. Cons—execution/timing risk, revenue volatility, and budget uncertainty; current price already near/above several targets ($20–$23 range), limiting immediate upside without new beats.

People Also Watch